Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis. It is an janus kinase 1 (JAK1) inhibitor.
Clinical trials
It is currently being evaluated in a phase 3 trials trial for the treatment of rheumatoid rthritis.
References